ProQR Therapeutics N.V. (PRQR)Healthcare | Biotechnology | Leiden, Netherlands | NasdaqCM
2.29 USD
-0.03
(-1.293%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.28 -0.01 (-0.008%) ⇩ (Aug. 28, 2026, 7:33 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:33 a.m. EDT
The immediate outlook is driven by a powerful convergence of insider accumulation and a massive shift in speculative positioning. Directors and insiders are aggressively buying shares, while the options chain reveals a 'gamma squeeze' setup with heavy call open interest at $5 and $7.50 strikes and virtually no defensive put writing. This suggests the market is pricing in a catalyst that could double the stock price soon. However, the long-term thesis faces a severe credibility gap. Despite the bullish sentiment, the company has burned through nearly $70 million in cash over the last nine years, resulting in a cumulative loss of over 58%. The business has been structurally deteriorating for years, with negative operating cash flow and no path to profitability visible in the current data. The current price is trading at a premium to book value despite these fundamental flaws. The tension here is stark: the short-term momentum is explosive due to insider confidence and options flow, but the long-term fundamentals are broken. Investors are betting on a binary event (a major clinical success or partnership) to reset the valuation, rather than a steady recovery of the current business model. Until the cash burn is addressed or a transformative milestone is achieved, the long-term risk remains extreme. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.148155 |
| AutoTheta | 0.173406 |
| AutoETS | 0.180841 |
| AutoARIMA | 0.183899 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 12.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.051 |
| Excess Kurtosis | -0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.266 |
| Revenue per Share | 0.173 |
| Market Cap | 323,162,592 |
| Forward P/E | -4.84 |
| Beta | 0.03 |
| Profit Margins | -228.18% |
| Website | https://www.proqr.com |
As of Aug. 22, 2026, 3:33 a.m. EDT: Options activity shows a distinct bullish skew with zero put volume and open interest recorded across all expirations. Call open interest is heavily concentrated at out-of-the-money strikes ($5.00 and $7.50), suggesting speculators are positioning for a significant upside move rather than hedging downside risk. Implied volatility remains elevated for calls relative to the flat put side, indicating a premium on potential gains.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.0 |
| Address1 | Zernikedreef 9 |
| All Time High | 27.6 |
| All Time Low | 0.53 |
| Ask | 2.3 |
| Ask Size | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,224,020 |
| Average Daily Volume3 Month | 1,106,525 |
| Average Volume | 1,106,525 |
| Average Volume10Days | 1,224,020 |
| Beta | 0.031 |
| Bid | 2.29 |
| Bid Size | 1 |
| Book Value | 0.8426131 |
| City | Leiden |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.29 |
| Current Ratio | 3.488 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.35 |
| Day Low | 2.275 |
| Debt To Equity | 19.266 |
| Display Name | ProQR Therapeutics |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -41,902,000 |
| Ebitda Margins | -2.27444 |
| Enterprise To Ebitda | -3.58 |
| Enterprise To Revenue | 8.142 |
| Enterprise Value | 149,992,224 |
| Eps Current Year | -0.462 |
| Eps Forward | -0.473 |
| Eps Trailing Twelve Months | -0.47 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.8782 |
| Fifty Day Average Change | 0.4117999 |
| Fifty Day Average Change Percent | 0.21925242 |
| Fifty Two Week Change Percent | 0.0 |
| Fifty Two Week High | 3.1 |
| Fifty Two Week High Change | -0.80999994 |
| Fifty Two Week High Change Percent | -0.2612903 |
| Fifty Two Week Low | 1.33 |
| Fifty Two Week Low Change | 0.9599999 |
| Fifty Two Week Low Change Percent | 0.72180444 |
| Fifty Two Week Range | 1.33 - 3.1 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,411,047,000,000 |
| Float Shares | 71,250,982 |
| Forward Eps | -0.473 |
| Forward P E | -4.841438 |
| Free Cashflow | -19,073,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 186 |
| Fullday Change | -0.03 |
| Fullday Change Percent | -1.2931 |
| Fullday Price | 2.2817 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 18,423,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17157 |
| Held Percent Institutions | 0.54501 |
| Implied Shares Outstanding | 141,119,032 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. |
| Long Name | ProQR Therapeutics N.V. |
| Market | us_market |
| Market Cap | 323,162,592 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_224193775 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -42,037,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 325,984,963 |
| Number Of Analyst Opinions | 9 |
| Open | 2.31 |
| Operating Cashflow | -49,007,000 |
| Operating Margins | -1.00719 |
| Payout Ratio | 0.0 |
| Phone | 31 88 166 7000 |
| Post Market Change | -0.008300066 |
| Post Market Change Percent | -0.3624483 |
| Post Market Price | 2.2817 |
| Post Market Time | 1,787,960,025 |
| Previous Close | 2.32 |
| Price Eps Current Year | -4.95671 |
| Price Hint | 4 |
| Price To Book | 2.717736 |
| Price To Sales Trailing12 Months | 17.541258 |
| Profit Margins | -2.28177 |
| Quick Ratio | 3.488 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -1.2931 |
| Regular Market Day High | 2.35 |
| Regular Market Day Low | 2.275 |
| Regular Market Day Range | 2.275 - 2.35 |
| Regular Market Open | 2.31 |
| Regular Market Previous Close | 2.32 |
| Regular Market Price | 2.29 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 458,209 |
| Return On Assets | -0.19759001 |
| Return On Equity | -0.57404 |
| Revenue Growth | 1.204 |
| Revenue Per Share | 0.173 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 141,119,032 |
| Shares Percent Shares Out | 0.015800001 |
| Shares Short | 2,224,351 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,308,954 |
| Short Name | ProQR Therapeutics N.V. |
| Short Percent Of Float | 0.0208 |
| Short Ratio | 2.84 |
| Source Interval | 15 |
| Symbol | PRQR |
| Target High Price | 12.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 8.22222 |
| Target Median Price | 8.0 |
| Total Cash | 117,125,000 |
| Total Cash Per Share | 1.065 |
| Total Debt | 15,312,000 |
| Total Revenue | 18,423,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.786425 |
| Two Hundred Day Average Change | 0.50357497 |
| Two Hundred Day Average Change Percent | 0.2818898 |
| Type Disp | Equity |
| Volume | 458,209 |
| Website | https://www.proqr.com |
| Zip | 2,333 CK |